To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.

Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Arms Length Body Publication (In consultation)
NICE

Feb. 10 2025

Source Page: Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]
Publication Type: Draft guidance
Document: Draft consultation document (downloadable version) PDF 251 KB (webpage)
Arms Length Body Publication (In consultation)
NICE

Feb. 10 2025

Source Page: Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]
Publication Type: Draft guidance
Document: Public committee slides PDF 561 KB (webpage)
Arms Length Body Publication (In consultation)
NICE

Feb. 10 2025

Source Page: Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]
Publication Type: Draft guidance
Document: Equality impact assessment (downloadable version) PDF 119 KB (webpage)
Arms Length Body Publication (In consultation)
NICE

Feb. 10 2025

Source Page: Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]
Publication Type: Draft guidance
Document: Committee papers PDF 7.2 MB (webpage)
Arms Length Body Publication (In development)
NICE

Feb. 10 2025

Source Page: Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]
Publication Type: Invitation to participate
Document: Final scope PDF 104 KB (webpage)
Arms Length Body Publication (In development)
NICE

Feb. 10 2025

Source Page: Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]
Publication Type: Invitation to participate
Document: Final stakeholder list PDF 93 KB (webpage)
Arms Length Body Publication (In development)
NICE

Feb. 10 2025

Source Page: Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]
Publication Type: Invitation to participate
Document: NICE's response to comments on the draft scope and provisional stakeholder list PDF 197 KB (webpage)
Arms Length Body Publication (In development)
NICE

Feb. 10 2025

Source Page: Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]
Publication Type: Invitation to participate
Document: Equality impact assessment (scoping) PDF 47 KB (webpage)
Arms Length Body Publication (In development)
NICE

Feb. 10 2025

Source Page: Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]
Publication Type: Invitation to participate
Document: NICE's response to comments on the draft scope and provisional stakeholder list PDF 229 KB (webpage)
Arms Length Body Publication (In development)
NICE

Feb. 10 2025

Source Page: Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]
Publication Type: Invitation to participate
Document: Final scope PDF 117 KB (webpage)